Kuros Biosciences AG Share Price Swiss Exchange
Equities
CH0011025217
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- CHF | - |
24/04 | Kuros Biosciences Posts Higher Q1 Product Sales | MT |
17/04 | Kuros Biosciences AG Approves Board of Director and Committee Changes | CI |
Sales 2022 | 1.8Cr 2.03Cr 169.91Cr | Sales 2023 | 3.36Cr 3.79Cr 317.08Cr | Capitalization | 13Cr 14Cr 1.21TCr |
---|---|---|---|---|---|
Net income 2022 | -1.4Cr -1.58Cr -132.26Cr | Net income 2023 | -1.3Cr -1.47Cr -122.81Cr | EV / Sales 2022 | 1.76 x |
Net cash position 2022 | 2.21Cr 2.5Cr 208.64Cr | Net cash position 2023 | 1.2Cr 1.36Cr 113.35Cr | EV / Sales 2023 | 3.46 x |
P/E ratio 2022 |
-3.41
x | P/E ratio 2023 |
-9.18
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 64.98% |
Managers | Title | Age | Since |
---|---|---|---|
Joost de Bruijn
FOU | Founder | 58 | 04/17/04 |
Christopher Fair
CEO | Chief Executive Officer | 54 | 19/21/19 |
Daniel Geiger
DFI | Director of Finance/CFO | - | 17/23/17 |
Members of the board | Title | Age | Since |
---|---|---|---|
Christopher Fair
CEO | Chief Executive Officer | 54 | 19/21/19 |
Joost de Bruijn
FOU | Founder | 58 | 04/17/04 |
Chairman | 67 | 23/17/23 |
1st Jan change | Capi. | |
---|---|---|
+20.03% | 13TCr | |
+23.61% | 12TCr | |
+23.26% | 2.75TCr | |
-18.07% | 2.09TCr | |
-15.13% | 1.7TCr | |
-14.81% | 1.63TCr | |
+9.78% | 1.46TCr | |
-46.10% | 1.51TCr | |
+52.34% | 1.39TCr |